Platelet aggregation and incident ischaemic heart disease in the Caerphilly cohort

P C Elwood, S Renaud, A D Beswick, J R O’Brien, P M Sweetnam

Abstract

Background—Platelets are involved in myocardial infarction but evidence of prediction of infarction by measures of platelet function are sparse.

Methods—Platelet aggregation to thrombin and to ADP in platelet rich plasma was recorded for 2176 men aged 49–65 years in the Caerphilly cohort study.

Results—Results from 364 men were excluded, 80 of whom had not fasted before venepuncture; most of the others were excluded because antiplatelet medication had been taken shortly before the platelet tests. During the five years following the platelet tests 113 ischaemic heart disease (IHD) events which fulfilled the World Health Organisation criteria were identified—42 fatal and 71 non-fatal. No measure of platelet aggregation was found to be significantly predictive of incident IHD. The possibility that platelet function is predictive for only a limited time after it is characterised, and that prediction falls off with time, was tested. When IHD events are grouped by their time of occurrence after aggregation had been measured, the test results show a gradient suggestive of prediction of early IHD events. Thus, 24% of the men who had an event within 500 days of the test had had a high secondary response to ADP while only 12% of those whose IHD event had been 1000 or more days after the test had shown a high platelet response at baseline. The trend in these proportions is not significant.

Conclusions—Platelet aggregation to thrombin and ADP in platelet rich plasma was recorded in the Caerphilly cohort study. No measure of aggregation was found to be predictive of IHD.

(Heart 1998;80:578–582)

Keywords: platelet aggregation; ischaemic heart disease; prediction

Evidence that platelets play a key role in ischaemic heart disease (IHD) comes from a wide variety of sources, including the histology of thrombi in the coronary vessels,1 the finding of platelet emboli in the microcirculation of the myocardium after sudden death,2 and the finding of an occlusive thrombus on angiography shortly after infarction.3 Animal studies confirm that platelet aggregates develop if the coronary vessel intima is damaged.4 A few case control studies show that platelet aggregation is enhanced after myocardial infarction5–7 and cross sectional evidence shows an association between aggregation and prevalent IHD.8–9

Further suggestive evidence of the relevance of platelets to myocardial infarction comes from the comparability of the diurnal patterns in aggregation and infarction,10–11 and from significant relations between platelet aggregation and certain risk factors for IHD.12 In addition, it has been reported that patients who died after a myocardial infarct had had larger, and therefore more active, platelets than those who survived.13 On the basis of a strong negative relation between alcohol intake and platelet aggregation,14 Renaud went on to suggest that a lower platelet sensitivity, through the consumption of red wine, may explain the reduced IHD mortality in France—the so called “French paradox”.14

The most persuasive evidence that platelet function is relevant to infarction comes, however, from trials of aspirin, in which a small dose of aspirin, sufficient to modify platelet aggregation, is associated with a 25–35% reduction in IHD incidence.15–16

Only two studies of the prediction of platelet aggregation for IHD appear to have been reported. These were both relatively small studies yet they detected significant prediction of coronary events and mortality in survivors of a myocardial infarct17 and in healthy men.18

We report here data from an ad hoc study of platelet aggregation and incident IHD in the Caerphilly cohort study.19 The work was approved by the South Glamorgan ethics committee, and all subjects gave informed signed consent.

Methods

SUBJECT

The Caerphilly cohort of 2512 men aged 45–59 years had been identified during the period 1979 to 1983.19 In the first re-examination of the men (phase II) five years later, tests of platelet aggregation were performed.

Men were seen at an afternoon/evening clinic for the collection of general data, including evidence of prevalent or past IHD. Each man was then asked to attend an early morning clinic, after an overnight fast, for venepuncture; for most the blood was taken between 06:00 and 09:00. The first 30 ml of blood taken was used for other tests, and the following 18 ml was drawn without stasis into 2 ml of fresh 0.13 M sodium citritate for the preparation of platelet rich plasma (PRP). Samples were kept at 30°C in a water bath and were spun within 10 minutes, at 3000 rpm for 10 minutes. Some of the plasma was removed, the sample spun
Platelet aggregation and ischaemic heart disease

measurements of the recorded tracings. Some
recorder. We therefore made a number of
of a platelet suspension, as traced by a pen
characterise the changes in the optical density
PRP
responses could be stated as both an absolute
density of PPP was also measured so that
changes in optical density recorded. The optical
density of PPP was also measured so that
responses could be stated as both an absolute
and change proportional to the
PRP-PPP difference.

No single measurement could adequately
calculate the changes in the optical density of
a platelet suspension, as traced by a pen
recorder. We therefore made a number of
measurements of the recorded tracings. Some
of these had been used in our earlier reports,21
but to these were added several further
measurements made on the pen recorder trac-
ings. We made numerous measurements on the
traces for the various agonists. We then
taken the reproducibility between the
duplicates of each of these, how well each
discriminated between subjects, and to what
extent they correlated with other measure-
ments. On the basis of this we selected a
number of measurements that appeared to be
different aspects of platelet function and were
largely independent of other measurements.
The following indices of platelet aggregation
are therefore used.

For the response to thrombin:
• the maximum increase in optical density
  following exposure to thrombin
• the time from the addition of thrombin, to
  the point at which the disaggregation, which
  followed aggregation, became maximal.

For the primary response to ADP:
• the maximum increase in optical density
  during the primary response
• the extent of recovery after the primary
  response.

For the secondary response to ADP:
• the increase in optical density during the
  secondary response at a fixed point exactly
  two minutes after exposure to ADP
• the pattern of the secondary response
  judged visually and graded as follows (where
  there was a difference between the duplicate
  traces, the higher of the two grades was
  used):
  (1) little primary or secondary aggregation
  (2) marked primary, little secondary aggrega-
  (3) slight secondary aggregation
  (4) two peaks, primary greater than secondary
  (5) slight primary, secondary plateau or in-
  creasing
  (6) two peaks, secondary greater than primary
  (7) marked primary into secondary
  (8) primary and secondary form a continuous
  response.

As with previous work,20 the results are pre-
Presented with the indices expressed as percent-
ages of the maximum possible aggregation,
except for the time to maximum recovery for
thrombin aggregation. In the analysis the effect
of using absolute changes and of allowing for
differences in the original platelet count were
investigated. Neither made any material differ-
ence.

Primary responses to ADP and the responses
to thrombin are unimodal,7 and are treated as
statistically normal. The distribution of the
secondary responses to ADP seems to be
bimodal8 and, as before, was dichotomised into
“high” and “low” responders.

INCIDENT DISEASE
Evidence on IHD events during the five years
following the baseline platelet tests was ob-
tained from death certificates, from hospital
records, and from repeated ECGs. The criteria
for a clinical event are based on the standard
World Health Organisation definitions, and are
described in detail elsewhere.21

Results
The cohort at the time of the first re-
examination comprised 2398 men aged 49–65
years. Tests of platelet aggregation were per-
formed on 2176 (90.7%) of these. Fasting blood
was not obtained from 80 men. The results from
these were excluded, together with those of a
further 284 men who had taken an antiplatelet
drug during the previous seven days. The five
year incidence of IHD in the men excluded
because of non-fasting or antiplatelet medi-
cation was considerably higher (10.2%) than in
the total cohort (6.7%). Satisfactory data were
obtained from 1809 men for aggregation to
ADP and from 1812 men to thrombin (table 1).

During the five years following the baseline
examination 113 IHD events occurred among
the 1812 men with a satisfactory measurement
of aggregation, 42 (37%) of which were fatal.
The predictive power of the aggregation tests
for these events is examined below. In order to

Table 1  Numbers of men in the cohort, numbers excluded,
and incidence of IHD

<table>
<thead>
<tr>
<th>Total number of men</th>
<th>Number (%) of men who experienced an IHD event</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total cohort</td>
<td>2398</td>
</tr>
<tr>
<td>Exclusions</td>
<td></td>
</tr>
<tr>
<td>No platelet function tests</td>
<td>222 11 (5.0%)</td>
</tr>
<tr>
<td>Not fasting</td>
<td>80 9 (11.3%)</td>
</tr>
<tr>
<td>Antiplatelet drugs in previous week</td>
<td>284 28 (9.9%)</td>
</tr>
<tr>
<td>Exclusions</td>
<td></td>
</tr>
<tr>
<td>With thrombin results</td>
<td>1812 113 (6.2%)</td>
</tr>
<tr>
<td>With ADP results</td>
<td>1809 113 (6.2%)</td>
</tr>
</tbody>
</table>

"high" and "low" responders.

INCIDENT DISEASE
Evidence on IHD events during the five years
following the baseline platelet tests was ob-
tained from death certificates, from hospital
records, and from repeated ECGs. The criteria
for a clinical event are based on the standard
World Health Organisation definitions, and are
described in detail elsewhere.21

INCIDENT DISEASE
Evidence on IHD events during the five years
following the baseline platelet tests was ob-
tained from death certificates, from hospital
records, and from repeated ECGs. The criteria
for a clinical event are based on the standard
World Health Organisation definitions, and are
described in detail elsewhere.21

Results
The cohort at the time of the first re-
examination comprised 2398 men aged 49–65
years. Tests of platelet aggregation were per-
formed on 2176 (90.7%) of these. Fasting blood
was not obtained from 80 men. The results from
these were excluded, together with those of a
further 284 men who had taken an antiplatelet
drug during the previous seven days. The five
year incidence of IHD in the men excluded
because of non-fasting or antiplatelet medi-
cation was considerably higher (10.2%) than in
the total cohort (6.7%). Satisfactory data were
obtained from 1809 men for aggregation to
ADP and from 1812 men to thrombin (table 1).

During the five years following the baseline
examination 113 IHD events occurred among
the 1812 men with a satisfactory measurement
of aggregation, 42 (37%) of which were fatal.
The predictive power of the aggregation tests
for these events is examined below. In order to

Table 1  Numbers of men in the cohort, numbers excluded,
and incidence of IHD

<table>
<thead>
<tr>
<th>Total number of men</th>
<th>Number (%) of men who experienced an IHD event</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total cohort</td>
<td>2398</td>
</tr>
<tr>
<td>Exclusions</td>
<td></td>
</tr>
<tr>
<td>No platelet function tests</td>
<td>222 11 (5.0%)</td>
</tr>
<tr>
<td>Not fasting</td>
<td>80 9 (11.3%)</td>
</tr>
<tr>
<td>Antiplatelet drugs in previous week</td>
<td>284 28 (9.9%)</td>
</tr>
<tr>
<td>Exclusions</td>
<td></td>
</tr>
<tr>
<td>With thrombin results</td>
<td>1812 113 (6.2%)</td>
</tr>
<tr>
<td>With ADP results</td>
<td>1809 113 (6.2%)</td>
</tr>
</tbody>
</table>
Table 2  Response to thrombin. Mean (SD) change in optical density on exposure of platelet rich plasma to thrombin, and time to maximum recovery after aggregation, in men who went on to experience an IHD event and in those who experienced no such event during the subsequent five years

<table>
<thead>
<tr>
<th>Pattern type</th>
<th>Number of men</th>
<th>Number who had shown a high secondary response</th>
</tr>
</thead>
<tbody>
<tr>
<td>No incident IHD event</td>
<td>1696</td>
<td>229 (14%)</td>
</tr>
<tr>
<td>An IHD event within 500 days</td>
<td>25</td>
<td>6 (24%)</td>
</tr>
<tr>
<td>500–999 days</td>
<td>23</td>
<td>5 (22%)</td>
</tr>
<tr>
<td>1000–1499 days</td>
<td>30</td>
<td>5 (17%)</td>
</tr>
<tr>
<td>1500 days or longer</td>
<td>20</td>
<td>1 (5%)</td>
</tr>
<tr>
<td>Unknown time*</td>
<td>15</td>
<td>1 (7%)</td>
</tr>
</tbody>
</table>

*Men with an ECG defined event and no symptomatic event.

Table 3  Primary response to ADP. Mean (SD) change in optical density during the primary wave of aggregation on exposure to ADP and the degree of recovery before the secondary wave of aggregation commenced

<table>
<thead>
<tr>
<th>Pattern type</th>
<th>Number of men</th>
<th>Number who had shown a high secondary response</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men who experienced no incident IHD event</td>
<td>1696</td>
<td>229 (14%)</td>
</tr>
<tr>
<td>Men who experienced an incident IHD event</td>
<td>25</td>
<td>6 (24%)</td>
</tr>
<tr>
<td>500 days</td>
<td>23</td>
<td>5 (22%)</td>
</tr>
<tr>
<td>1500 days or longer</td>
<td>20</td>
<td>1 (5%)</td>
</tr>
</tbody>
</table>

Table 4  Secondary response to ADP. Numbers of men with a “low” and a “high” secondary response to ADP and the relative odds for an IHD occurring within the men so defined

<table>
<thead>
<tr>
<th>Pattern type</th>
<th>Number of men</th>
<th>Number who had shown a high secondary response</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low secondary response</td>
<td>1467</td>
<td>95 (6.1%)</td>
</tr>
<tr>
<td>High secondary response</td>
<td>229</td>
<td>18 (7.3%)</td>
</tr>
</tbody>
</table>

Table 5  Pattern of secondary response to ADP

Table 6  Pattern of secondary response to ADP

Examine the possibility that prediction might fall off with time, we also examined aggregation in men who had an incident IHD event within various intervals after the baseline tests (less than 500 days, 500 to 999 days, and so on).

Table 2 summarises the data for aggregation to thrombin. Both the mean decrease in optical density and the time to maximum recovery after aggregation are virtually identical in the 113 men who experienced an IHD event and the men who did not. Furthermore, there is no evidence of significant differences in aggregation in the men who experienced an IHD event within 1000 days (approximately three years) of the tests. Standardisation for various combinations of smoking habit, time since last cigarette, and alcohol consumption had virtually no effect.

Table 3 shows the same data for the primary response to ADP. Again there is no evidence of any prediction, either for IHD events within the five years, or within the first three years of follow up. Standardisation for possible confounding by smoking and alcohol consumption made virtually no difference.

Earlier work on prevalent IHD had shown that the aspect of aggregation which appeared to be most closely associated with prevalent IHD was secondary aggregation to ADP. The results for this test were therefore examined closely. Table 4 shows that among the men who had shown a high response to ADP 7.3% had experienced an incident IHD event during the following five years. This is slightly higher than the proportion among the men who had shown less active responses to ADP, (6.1%) but the difference is not significant. The odds of an event in these men, compared to men with a low response, was 1.21 (not significant), and standardisation of this for possible confounding makes little difference.

Table 5 displays these secondary responses to ADP grouped by the time after the tests within which the IHD events had occurred. There is a suggestion of a gradient in that, of the men who had an IHD event within 500 days after the platelet test, 24% had shown a high response to ADP and this proportion decreased steadily, with only 12% of those whose IHD event occurred 1000 or more days after the test having had a high response. A log rank test to compare the time pattern of incident IHD in “low” and “high” secondary ADP response groups yields a $\chi^2$ (1 degree of freedom) of 1.25 ($p = 0.26$).

There was very great variability in the pattern of the waves of secondary aggregation to ADP. Table 6 displays the numbers who had shown various patterns, as judged by eye. It would have seemed reasonable to have predicted that a marked secondary wave would be predictive—that is, the patterns 6, 7, and 8 as we had defined them. Men with these patterns, however, show no stronger prediction than the others.

Discussion

We have failed to show any useful prediction of IHD by platelet aggregation to a number of agonists, including ADP. The only possible exception arises from a post hoc examination of the secondary response to ADP and early
IHD events (table 5). We regard this as special pleading, as a distinction between early and later IHD events had not been part of our original intentions. However, the time to infarction should perhaps be considered in any future examination of prediction by platelet aggregation.

Two studies have shown significant prediction from platelet aggregation. Trip et al recorded spontaneous platelet aggregation—that is, aggregation occurring on stirring PRP, without the addition of any agonist.17 During a five year follow up of 149 postinfarction patients there was a strong relation with the incidence of IHD events; the 26 patients who had shown definite spontaneous aggregation had a relative risk of death of 5.4, and a relative risk for an IHD event of 3.1, relative to the 94 patients who had shown no spontaneous aggregation (both significant). On the other hand, Thaulow et al examined prediction by aggregation to ADP, adrenaline, and collagen in 487 healthy men aged 40–59 years.18 No significant prediction was observed for adrenaline or collagen, but the 75 men with the fastest ADP induced aggregation rates had significantly higher coronary heart disease mortality than the 75 men with the slowest aggregation (p < 0.01).

We did not measure spontaneous aggregations, nor did we measure the time to incipient ADP aggregation as done by Thaulow et al. In our hands the time between exposure to an agonist and the commencement was so short that it was almost unmeasurable. On the other hand, as described earlier, we made numerous measurements on the traces from each agonist, and we examined prediction by all those that appeared to give independent and reproducible evidence on the platelet response.

Uncertainty may arise from our method of estimation of aggregation, in particular the use of a single dose of each agonist. The recording of aggregation is difficult and time consuming and, because of our desire to do the tests with fasting blood, it was only possible to complete all the tests in duplicate on six subjects each morning. It was therefore assumed that the best use of resources would be to record responses to single doses of each agonist in the belief that a single measurement on a large cohort would enable prediction to be tested more efficiently than multiple estimates made with different doses of agonists, on a smaller number of subjects. We have no evidence to judge whether we were wrong in this assumption.

We would judge, however, that the techniques we used are reasonable and the results they produced meaningful. The platelet aggregation results, which are the subject of this report, were found to show strong and significant relations between the responses to ADP and alcohol intake.19 In another study in which we used precisely these techniques we detected significantly reduced secondary ADP aggregation in subjects whose fat intake had been modified.20 Using the same techniques and apparatus, one of us (SR) found differences in aggregation in subjects living in regions with differing rates of coronary heart disease.21 These results would seem to remove most of the doubt as to the appropriateness of the aggregation techniques used by us.

The study may have lost some power because of exclusions. The aggregation results for 284 men, many of whom had been on aspirin, were omitted, together with the results for 80 men who had not fasted before venesection. The IHD incidences in these men were 9.9% and 11.3%, respectively, and both these are significantly greater than the proportion of the other men who experienced an IHD event. This implies that the results of some of the men at greatest risk of IHD, and possibly with the most active platelets, were omitted. Although this was outside our control, the omission of these men represents bias. At the same time, it would seem unlikely that any worthwhile predictive effect would have been totally missed because of these exclusions.

More fundamental uncertainties arise, however, from uncertainties as to the relevance of any in vitro test to platelet function in vivo. The characterisation of a physiological function is clearly very different from the simple measurement of the concentration of a haemostatic or other factor involved in health or disease. In the case of platelets, the preparation of PRP may change the platelets, and exposure to a single agonist within a test tube may inadequately mimic what happens around an atherosclerotic plaque in a coronary vessel. No acceptable experimental approach can avoid all these unrealities, though animal models such as that developed by Folts and his colleagues, in which a coronary artery of a dog is experimentally damaged,14,24 may approach the real life situation.

One approach which removes some of the unrealities in the PRP tests is to use whole blood. We have included such a test in a later examination of the same cohort1 and evaluation against incident IHD events will become possible in a few years. A pilot run of this test was, however, undertaken on a small sample of 308 men seen towards the end of the examination described in this report, and the methods used and a preliminary examination of the results has already been published.23 Results of this test, done with ADP, correlates only poorly with the test done with ADP on PRP from the same men (r = 0.22), suggesting that the two approaches, using PRP and whole blood, may reflect different aspects of in vivo platelet function. Evaluation of this test against incident IHD will be of interest.

A measure of platelet activity which is predictive of IHD events could be of very great value in clinical practice. Low dose aspirin is an effective prophylactic against thromboembolic conditions and this is believed to be through its antiplatelet action. A test of platelet function could therefore be used as a screening procedure which might enable low dose aspirin prophylaxis to be targeted towards patients found to have more highly reactive platelets. Furthermore, an approach along these lines might be used to enhance the power of trials to evaluate primary prevention by aspirin.
The present data provide no convincing evidence that a single measure of platelet aggregation, as it was done under “field” conditions in the Caerphilly study, is relevant to IHD events which occur later.

The work described was supported by the UK Medical Research Council.

Platelet aggregation and incident ischaemic heart disease in the Caerphilly cohort

P C Elwood, S Renaud, A D Beswick, J R O'Brien and P M Sweetnam

*Heart* 1998 80: 578-582
doi: 10.1136/hrt.80.6.578

Updated information and services can be found at:
http://heart.bmj.com/content/80/6/578

These include:

**References**

This article cites 24 articles, 8 of which you can access for free at:
http://heart.bmj.com/content/80/6/578#BIBL

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections

- Drugs: cardiovascular system (8842)
- Epidemiology (3752)
- Acute coronary syndromes (2742)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/